About Paragon Pharmacies
Paragon Pharmacies Ltd. Incorporated in 2002, with a view to becoming a player in the Canadian pharmacy industry, Paragon is built on a foundation of successful pharmacy operations and is purchasing independent pharmacies at attractive valuations in western Canada. Given the phenomenal valuation growth experienced by national drug chains, Paragon is developing a presence of community-oriented pharmacies across the country with an initial focus on the western Canadian market. www.paragonpharmacies.com
Missing: Paragon Pharmacies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Paragon Pharmacies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Paragon Pharmacies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Paragon Pharmacies is included in 1 Expert Collection, including Pharma Supply Chain.
Pharma Supply Chain
Paragon Pharmacies Frequently Asked Questions (FAQ)
When was Paragon Pharmacies founded?
Paragon Pharmacies was founded in 2002.
What is Paragon Pharmacies's latest funding round?
Paragon Pharmacies's latest funding round is Other Investors.
Who are the investors of Paragon Pharmacies?
Investors of Paragon Pharmacies include Envoy Capital Management.
Who are Paragon Pharmacies's competitors?
Competitors of Paragon Pharmacies include Adamas Pharmaceuticals, Invistics, InClinica, AkaRx, Omthera Pharmaceuticals and 12 more.
Compare Paragon Pharmacies to Competitors
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.
Pet Medicus Laboratories is a specialty pharmaceutical company that is engaged in the formulation, clinical testing, federal registration, manufacture, and sale of drug products for the companion animal market.
Apath is a pharmaceutical discovery and development company with a focus on the hepatitis C virus ("HCV") and other human viral pathogens. Apath was founded by Charles M. Rice, Ph.D., currently Professor of Molecular Microbiology, Rockefeller University and formerly of the Washington University (St. Louis) School of Medicine. Apath is engaged in the commercial application of virology and viral genetics to discover and develop a broad range of diagnostic and therapeutic products for viral infections, and for applications using viruses as vectors. Apath's primary focus is on RNA viruses. RNA viruses account for the majority of viruses which are human pathogens. In addition to HCV, they include several medically important viruses such as influenza, respiratory syncytial virus ("RSV"), and hemorrhagic fever viruses (e.g., Ebola).
Altea Therapeutics is using advanced delivery across the skin that aim to improve the efficacy, safety and compliance of drugs and vaccines.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.